Literature DB >> 25481106

Prolonged exposure to high and variable phenylalanine levels over the lifetime predicts brain white matter integrity in children with phenylketonuria.

Anna Hood1, Jo Ann V Antenor-Dorsey2, Jerrel Rutlin2, Tamara Hershey3, Joshua S Shimony4, Robert C McKinstry5, Dorothy K Grange6, Shawn E Christ7, Robert Steiner8, Desiree A White9.   

Abstract

In this study, we retrospectively examined the microstructural white matter integrity of children with early- and continuously-treated PKU (N=36) in relation to multiple indices of phenylalanine (Phe) control over the lifetime. White matter integrity was assessed using mean diffusivity (MD) from diffusion tensor imaging (DTI). Eight lifetime indices of Phe control were computed to reflect average Phe (mean, index of dietary control), variability in Phe (standard deviation, standard error of estimate, % spikes), change in Phe with age (slope), and prolonged exposure to Phe (mean exposure, standard deviation exposure). Of these indices, mean Phe, mean exposure, and standard deviation exposure were the most powerful predictors of widespread microstructural white matter integrity compromise. Findings from the two previously unexamined exposure indices reflected the accumulative effects of elevations and variability in Phe. Given that prolonged exposure to elevated and variable Phe was particularly detrimental to white matter integrity, Phe should be carefully monitored and controlled throughout childhood, without liberalization of Phe control as children with PKU age.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Brain; Diffusion tensor imaging; Exposure; Phenylalanine; Phenylketonuria; White matter

Mesh:

Substances:

Year:  2014        PMID: 25481106      PMCID: PMC4277899          DOI: 10.1016/j.ymgme.2014.11.007

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  36 in total

1.  Toward using confidence intervals to compare correlations.

Authors:  Guang Yong Zou
Journal:  Psychol Methods       Date:  2007-12

Review 2.  National Institutes of Health Consensus Development Conference Statement: phenylketonuria: screening and management, October 16-18, 2000.

Authors: 
Journal:  Pediatrics       Date:  2001-10       Impact factor: 7.124

Review 3.  Executive function in early-treated phenylketonuria: profile and underlying mechanisms.

Authors:  Shawn E Christ; Stephan C J Huijbregts; Leo M J de Sonneville; Desirée A White
Journal:  Mol Genet Metab       Date:  2010       Impact factor: 4.797

4.  Psychiatric symptoms and disorders in phenylketonuria.

Authors:  V L Brumm; D Bilder; S E Waisbren
Journal:  Mol Genet Metab       Date:  2010       Impact factor: 4.797

5.  Tract-based evaluation of white matter damage in individuals with early-treated phenylketonuria.

Authors:  Huiling Peng; Dawn Peck; Desirée A White; Shawn E Christ
Journal:  J Inherit Metab Dis       Date:  2013-09-17       Impact factor: 4.982

6.  Phenylketonuria: white-matter changes assessed by 3.0-T magnetic resonance (MR) imaging, MR spectroscopy and MR diffusion.

Authors:  T Scarabino; T Popolizio; M Tosetti; D Montanaro; G M Giannatempo; R Terlizzi; S Pollice; A Maiorana; N Maggialetti; A Carriero; V Leuzzi; U Salvolini
Journal:  Radiol Med       Date:  2009-03-10       Impact factor: 3.469

7.  Phenylketonuria: High plasma phenylalanine decreases cerebral protein synthesis.

Authors:  Marieke Hoeksma; Dirk-Jan Reijngoud; Jan Pruim; Harold W de Valk; Anne M J Paans; Francjan J van Spronsen
Journal:  Mol Genet Metab       Date:  2009-02-06       Impact factor: 4.797

8.  White matter integrity and executive abilities following treatment with tetrahydrobiopterin (BH4) in individuals with phenylketonuria.

Authors:  Desirée A White; Jo Ann V Antenor-Dorsey; Dorothy K Grange; Tamara Hershey; Jerrel Rutlin; Joshua S Shimony; Robert C McKinstry; Shawn E Christ
Journal:  Mol Genet Metab       Date:  2013-07-19       Impact factor: 4.797

9.  The pathogenesis of the white matter abnormalities in phenylketonuria. A multimodal 3.0 tesla MRI and magnetic resonance spectroscopy (1H MRS) study.

Authors:  V Leuzzi; M Tosetti; D Montanaro; C Carducci; C Artiola; C Carducci; I Antonozzi; M Burroni; F Carnevale; F Chiarotti; T Popolizio; G M Giannatempo; V D'Alesio; T Scarabino
Journal:  J Inherit Metab Dis       Date:  2007-01-23       Impact factor: 4.750

10.  Apparent diffusion coefficient restriction in the white matter: going beyond acute brain territorial ischemia.

Authors:  Valentina Citton; Alberto Burlina; Claudio Baracchini; Massimo Gallucci; Alessia Catalucci; Sandro Dal Pos; Alessandro Burlina; Renzo Manara
Journal:  Insights Imaging       Date:  2011-12-20
View more
  16 in total

1.  Biochemical markers and neuropsychological functioning in distal urea cycle disorders.

Authors:  Susan E Waisbren; David Cuthbertson; Peter Burgard; Amy Holbert; Robert McCarter; Stephen Cederbaum
Journal:  J Inherit Metab Dis       Date:  2018-02-08       Impact factor: 4.982

2.  Brain White Matter Integrity Mediates the Relationship Between Phenylalanine Control and Executive Abilities in Children with Phenylketonuria.

Authors:  Anna Hood; Jerrel Rutlin; Joshua S Shimony; Dorothy K Grange; Desiree A White
Journal:  JIMD Rep       Date:  2016-07-22

Review 3.  The complete European guidelines on phenylketonuria: diagnosis and treatment.

Authors:  A M J van Wegberg; A MacDonald; K Ahring; A Bélanger-Quintana; N Blau; A M Bosch; A Burlina; J Campistol; F Feillet; M Giżewska; S C Huijbregts; S Kearney; V Leuzzi; F Maillot; A C Muntau; M van Rijn; F Trefz; J H Walter; F J van Spronsen
Journal:  Orphanet J Rare Dis       Date:  2017-10-12       Impact factor: 4.123

4.  Novel imaging technologies for genetic diagnoses in the inborn errors of metabolism.

Authors:  Andrea L Gropman; Afrouz Anderson
Journal:  J Transl Genet Genom       Date:  2020-11-13

5.  Effect of dietary regime on metabolic control in phenylketonuria: Is exact calculation of phenylalanine intake really necessary?

Authors:  Carmen Rohde; Alena Gerlinde Thiele; Ulrike Och; Katrin Schönherr; Uta Meyer; Stefanie Rosenbaum-Fabian; Cornelia Maddalon; Sabine Matzken; Holger Blessing; Frauke Lang; Monika Jörg-Streller; Skadi Beblo
Journal:  Mol Genet Metab Rep       Date:  2015-10-22

6.  The Predictive Value of Genetic Analyses in the Diagnosis of Tetrahydrobiopterin (BH4)-Responsiveness in Chinese Phenylalanine Hydroxylase Deficiency Patients.

Authors:  Tianwen Zhu; Jun Ye; Lianshu Han; Wenjuan Qiu; Huiwen Zhang; Lili Liang; Xuefan Gu
Journal:  Sci Rep       Date:  2017-07-28       Impact factor: 4.379

7.  Pretreatment cognitive and neural differences between sapropterin dihydrochloride responders and non-responders with phenylketonuria.

Authors:  Zoë Hawks; Joshua Shimony; Jerrel Rutlin; Dorothy K Grange; Shawn E Christ; Desirée A White
Journal:  Mol Genet Metab Rep       Date:  2017-02-23

8.  Clinical and neuropsychological outcomes for children with phenylketonuria in Upper Egypt; a single-center study over 5 years.

Authors:  Abdelrahim A Sadek; Mohammed H Hassan; Nesreen A Mohammed
Journal:  Neuropsychiatr Dis Treat       Date:  2018-10-05       Impact factor: 2.570

9.  Relationship between age and white matter integrity in children with phenylketonuria.

Authors:  Erika Wesonga; Joshua S Shimony; Jerrel Rutlin; Dorothy K Grange; Desiree A White
Journal:  Mol Genet Metab Rep       Date:  2016-04-08

10.  White matter microstructural damage in early treated phenylketonuric patients.

Authors:  María Julieta González; Mónica Rebollo Polo; Pablo Ripollés; Rosa Gassió; Aída Ormazabal; Cristina Sierra; Roser Colomé Roura; Rafael Artuch; Jaume Campistol
Journal:  Orphanet J Rare Dis       Date:  2018-10-26       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.